226 related articles for article (PubMed ID: 33655395)
1. Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy.
Narayanaswamy R; Torchilin VP
Pharm Res; 2021 Mar; 38(3):429-450. PubMed ID: 33655395
[TBL] [Abstract][Full Text] [Related]
2. Antibody-conjugated pH-sensitive liposomes for HER-2 positive breast cancer: development, characterization,
Raikwar S; Yadav V; Jain S; Jain SK
J Liposome Res; 2024 Jun; 34(2):239-263. PubMed ID: 37594466
[TBL] [Abstract][Full Text] [Related]
3. CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel.
Muntimadugu E; Kumar R; Saladi S; Rafeeqi TA; Khan W
Colloids Surf B Biointerfaces; 2016 Jul; 143():532-546. PubMed ID: 27045981
[TBL] [Abstract][Full Text] [Related]
4. Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells.
Zhou J; Sun M; Jin S; Fan L; Zhu W; Sui X; Cao L; Yang C; Han C
Drug Deliv; 2019 Dec; 26(1):281-289. PubMed ID: 30880491
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells.
Yang T; Choi MK; Cui FD; Lee SJ; Chung SJ; Shim CK; Kim DD
Pharm Res; 2007 Dec; 24(12):2402-11. PubMed ID: 17828616
[TBL] [Abstract][Full Text] [Related]
6. Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy.
Eloy JO; Petrilli R; Topan JF; Antonio HMR; Barcellos JPA; Chesca DL; Serafini LN; Tiezzi DG; Lee RJ; Marchetti JM
Colloids Surf B Biointerfaces; 2016 May; 141():74-82. PubMed ID: 26836480
[TBL] [Abstract][Full Text] [Related]
7. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.
Gholizadeh S; Dolman EM; Wieriks R; Sparidans RW; Hennink WE; Kok RJ
Pharm Res; 2018 Mar; 35(4):85. PubMed ID: 29516187
[TBL] [Abstract][Full Text] [Related]
8. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles.
Zhang Y; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2012 Jan; 33(2):679-91. PubMed ID: 22019123
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity.
Koren E; Apte A; Jani A; Torchilin VP
J Control Release; 2012 Jun; 160(2):264-73. PubMed ID: 22182771
[TBL] [Abstract][Full Text] [Related]
10. PEGylated-Paclitaxel and Dihydroartemisinin Nanoparticles for Simultaneously Delivering Paclitaxel and Dihydroartemisinin to Colorectal Cancer.
Phung CD; Le TG; Nguyen VH; Vu TT; Nguyen HQ; Kim JO; Yong CS; Nguyen CN
Pharm Res; 2020 Jun; 37(7):129. PubMed ID: 32548664
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.
Gupta B; Torchilin VP
Cancer Immunol Immunother; 2007 Aug; 56(8):1215-23. PubMed ID: 17219149
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.
Apte A; Koren E; Koshkaryev A; Torchilin VP
Cancer Biol Ther; 2014 Jan; 15(1):69-80. PubMed ID: 24145298
[TBL] [Abstract][Full Text] [Related]
14. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
Elbayoumi TA; Torchilin VP
Eur J Pharm Sci; 2007 Nov; 32(3):159-68. PubMed ID: 17707615
[TBL] [Abstract][Full Text] [Related]
16. Combination of drug-conjugated SWCNT nanocarriers for efficient therapy of cancer stem cells in a breast cancer animal model.
Al Faraj A; Shaik AS; Ratemi E; Halwani R
J Control Release; 2016 Mar; 225():240-51. PubMed ID: 26827662
[TBL] [Abstract][Full Text] [Related]
17. Vitamin E-based redox-sensitive salinomycin prodrug-nanosystem with paclitaxel loaded for cancer targeted and combined chemotherapy.
Liang DS; Liu J; Peng TX; Peng H; Guo F; Zhong HJ
Colloids Surf B Biointerfaces; 2018 Dec; 172():506-516. PubMed ID: 30212688
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer.
Tang H; Chen J; Wang L; Li Q; Yang Y; Lv Z; Bao H; Li Y; Luan X; Li Y; Ren Z; Zhou X; Cong D; Liu Z; Jia J; Chen H; Zhao W; Meng Q; Sun F; Pei J
Int J Pharm; 2020 Jan; 573():118806. PubMed ID: 31678519
[TBL] [Abstract][Full Text] [Related]
19. Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes.
Niu R; Zhao P; Wang H; Yu M; Cao S; Zhang F; Chang J
J Drug Target; 2011 Jun; 19(5):373-81. PubMed ID: 20677917
[TBL] [Abstract][Full Text] [Related]
20. Co-Delivery of Docetaxel and Salinomycin to Target Both Breast Cancer Cells and Stem Cells by PLGA/TPGS Nanoparticles.
Gao J; Liu J; Xie F; Lu Y; Yin C; Shen X
Int J Nanomedicine; 2019; 14():9199-9216. PubMed ID: 32063706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
